Mus vs Palestine: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Mus
98.0%
in 2025
Palestine
99.0%
in 2025
Mus rank
1st
Palestine rank
1st
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Mus
- Palestine
How they compare
Palestine currently reports 99.0% against 98.0% in Mus, a difference of 1.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was Palestine ahead.
Mus ranks 1st and Palestine ranks 1st of 2 regions.
Palestine has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Mus | Palestine | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | — |
| 2010s | 28.7% | 71.3% | 42.6% | Palestine |
| 2020s | 95.0% | 96.2% | 1.2% | Palestine |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Mus or Palestine?
- Palestine, at 99.0% against 98.0% in Mus as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Mus and Palestine?
- 1.0%, with Palestine ahead.
- How many years of comparable data are there for Mus and Palestine?
- 18 years are reported by both, from 2008 to 2025.
- How do Mus and Palestine rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Mus ranks 1st and Palestine ranks 1st of 2 regions.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.